TMDX Stock Forecast & Price Target

TransMedics Group is viewed positively because its OCS platform and National OCS Program directly attack a large, structurally underpenetrated transplant market by improving organ utilization, expanding access to marginal donors, and potentially converting historically unusable organs into transplantable ones, with the technology addressable market estimated at nearly $8B across lung, heart, and liver. The company’s fundamental setup also looks stronger because 2025 total sales reached $605 million, representing 37% growth versus 2024, while management expects clearer financial parameters, higher liver share than in 2025 by the end of 2026, and a cost base being built in 2026 ahead of revenue reacceleration in 2027 as ENHANCE Part B, DENOVO, CHOPS, OCS Kidney, and Italy/OUS expansion layer onto the core business. In addition, the investment case is supported by improving clinical differentiation and commercialization leverage, including statistically meaningful survival benefits shown in OCS Liver data, a PMA supplement that could expand on-label use across roughly 20-30% of the US liver market, and operational evidence that double-shifting aircraft improved utilization, service margins, and mission availability, all of which strengthen the moat and long-term operating leverage.

TransMedics Group is facing a less compelling fundamental setup because the company’s growth narrative is already being measured against rising expectations, yet the implied 2026 revenue outcomes of roughly $738M to $749M suggest only modest upside around the $742M midpoint of guidance while the analyst still sees top-line optimism as “somewhat tempered.” The margin story also looks difficult, since 1Q26 adjusted opex of $83M was above expectations, FY26 interest expense is rising to $28.8M from new headquarters lease costs, and management’s implied step-down to about $79M of average quarterly opex from 2Q26-4Q26 may prove challenging given 2H-weighted spending, ongoing international expansion, and the possibility of additional incremental expenses. Competitive and execution risks further cloud the outlook, as Terumo’s OrganOx is guided to about +40% y/y growth in fiscal 2026, the company still faces regulatory and manufacturing validation hurdles for CHOPS, and the stock’s 3.3x STM sales valuation sits below its 2-year/5-year averages and at about a -1x turn discount to peers despite only modest evidence that the current growth rate can sustainably justify a re-rating.